Ohm, This presents a narrower path to approval.
Post# of 151587
(Total Views: 623)
Posted On: 01/20/2021 1:38:38 AM
Ohm,
This presents a narrower path to approval. I agree with your assessment. I would be anxious as a shareholder.
The flip side is that this will define a use for Lenzilumab or get it out of the picture. Send it back to Car-T land.
The world does not need an mAb equivalent to remdesivir.
This presents a narrower path to approval. I agree with your assessment. I would be anxious as a shareholder.
The flip side is that this will define a use for Lenzilumab or get it out of the picture. Send it back to Car-T land.
The world does not need an mAb equivalent to remdesivir.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼